Milestone Pharmaceuticals Receives Nasdaq Noncompliance Notice Over Minimum Bid Price

• Milestone Pharmaceuticals received a Nasdaq noncompliance notice October 23, 2026, following 30 consecutive business days below the $1 minimum bid price.
• The 180-day compliance period ends April 21, 2027; regaining compliance requires closing bids of at least $1 for 10 consecutive business days.
• The notice has no immediate impact on the common shares’ Nasdaq Global Select Market listing.
• A transfer to the Nasdaq Capital Market could provide additional compliance time, subject to eligibility; a reverse stock split remains an option.
• Failure to regain compliance within the allotted periods would trigger a delisting notice, which could be appealed to a Hearings Panel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Milestone Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-119669), on October 28, 2026, and is solely responsible for the information contained therein.